Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Bivalent influenza modRNA vaccine - BioNTech/Pfizer

Next Previous
Drug Profile

Bivalent influenza modRNA vaccine - BioNTech/Pfizer

Alternative Names: bIRV - BioNTech/Pfizer

Latest Information Update: 28 Oct 2024

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator BioNTech
  • Developer BioNTech; Pfizer
  • Class Influenza virus vaccines; RNA vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • No development reported Influenza virus infections

Most Recent Events

  • 28 Oct 2024 No recent reports of development identified for phase-I development in Influenza-virus-infections(In the elderly, Prevention) in USA (IM, Injection)
  • 27 Jan 2023 Pfizer completes a phase I trials in Influenza virus infections (Prevention, In the elderly) in USA (IM) (NCT05052697)
  • 05 Oct 2021 Bivalent influenza modRNA vaccine is available for licensing as of 05 Oct 2021. https://biontech.de/our-dna/collaborators

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top